Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 16.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 273,135 shares of the company’s stock after buying an additional 38,944 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Janux Therapeutics were worth $14,624,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Proficio Capital Partners LLC acquired a new position in Janux Therapeutics in the 4th quarter valued at about $1,353,000. HealthInvest Partners AB purchased a new position in shares of Janux Therapeutics in the fourth quarter valued at approximately $2,078,000. Handelsbanken Fonder AB acquired a new position in shares of Janux Therapeutics in the fourth quarter valued at approximately $642,000. New York State Common Retirement Fund grew its holdings in shares of Janux Therapeutics by 84.6% in the fourth quarter. New York State Common Retirement Fund now owns 15,964 shares of the company’s stock valued at $855,000 after purchasing an additional 7,318 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock worth $2,043,000 after buying an additional 599 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on JANX shares. Stifel Nicolaus raised their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. BTIG Research lifted their target price on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Finally, William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Janux Therapeutics has an average rating of “Buy” and a consensus price target of $92.44.

Insider Activity

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the transaction, the insider now owns 82,139 shares of the company’s stock, valued at $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. acquired 341,742 shares of Janux Therapeutics stock in a transaction on Wednesday, March 5th. The stock was purchased at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now owns 9,658,988 shares of the company’s stock, valued at $295,951,392.32. The trade was a 3.67 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 50,002 shares of company stock worth $2,684,703. Corporate insiders own 29.40% of the company’s stock.

Janux Therapeutics Stock Performance

JANX opened at $30.43 on Friday. Janux Therapeutics, Inc. has a one year low of $28.92 and a one year high of $71.71. The company has a market cap of $1.80 billion, a P/E ratio of -26.01 and a beta of 3.23. The business’s 50-day simple moving average is $37.22 and its 200-day simple moving average is $46.56.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.